Drug Profile
Ethinylestradiol/gestodene triphasic
Alternative Names: Gestodene/ethinylestadiol triphasic; Milvane; Phaeva; Tri Femoden; Tri Gynera; Tri-Minulet; Triadene; Trigynera; Trigynovin; Triminulet; Triminulet 28; Triodeen; Trioden ED; Triodena; TriodeneLatest Information Update: 09 Feb 2015
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Akromed; Bayer HealthCare Pharmaceuticals; Wyeth
- Class Alkylated estrogenic steroids; Norpregnatrienes; Norpregnenes
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pregnancy
Most Recent Events
- 09 Feb 2015 Launched for Contraception/Pregnancy (Prevention) in Denmark, Poland and Hungary (PO) prior to February 2015
- 16 Oct 2009 Wyeth has been acquired by Pfizer
- 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG